

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/67291> holds various files of this Leiden University dissertation.

Author: Brussee, J.M.

Title: First-pass and systemic metabolism of cytochrome P450 3A substrates in neonates, infants, and children

Issue Date: 2018-12-04

**First-pass and systemic metabolism of cytochrome
P450 3A substrates in neonates, infants, and children**

J.M. BRUSSEE

The research described in this thesis was performed at the division of Systems Biomedicine and Pharmacology of the Leiden Academic Centre for Drug Research (LACDR), Leiden University, the Netherlands. The research was financially supported by a Vidi grant (Vidi Knibbe 2013) of the Netherlands Organization for Scientific Research (NWO).

Printing of this thesis was financially supported by the Leiden Academic Centre for Drug Research.

Cover design: Dirk van Rijn, Paul Brussee, Jantine Brussee, and Proefschriften.nl

Printed by Proefschriften.nl

ISBN: 978-94-6332-426-7

© J.M. Brussee, 2018

All rights reserved. No parts of this thesis may be reproduced in any form or by any means without permission of the author.

**First-pass and systemic metabolism of cytochrome
P450 3A substrates in neonates, infants, and children**

PROEFSCHRIFT

ter verkrijging van
de graad van Doctor aan de Universiteit Leiden,
op gezag van Rector Magnificus prof. mr. C.J.J.M. Stolker,
volgens besluit van het College voor Promoties,
te verdedigen op dinsdag 4 december 2018
klokke 16.15 uur

door

Janneke Maria Brussee
geboren te Oegstgeest, Nederland
in 1989

Promotoren: prof. dr. C.A.J. Knibbe
prof. dr. S.N. de Wildt (Radboud UMC)

Copromotor: dr. E.H.J. Krekels

Promotiecommissie: prof. dr. H. Irth (voorzitter)
prof. dr. J.A. Bouwstra (secretaris)
prof. dr. M. Danhof
prof. dr. A.H.J. Mathijssen (Erasmus MC)
prof. dr. R.A.A. Mathôt (AMC)

Voor Sander

TABLE OF CONTENTS

Section I	General introduction and background	9
Chapter 1	First-pass and systemic metabolism of cytochrome P450 3A substrates in neonates, infants, and children – General introduction, Scope, and Outline	11
Chapter 2	Children in clinical trials: towards evidence-based pediatric pharmacotherapy using pharmacokinetic-pharmacodynamic modelling	23
Section II	Systemic CYP3A-mediated metabolism in critically ill children	49
Chapter 3	Inflammation and organ failure severely affect midazolam clearance in critically ill children	51
Chapter 4	Predicting CYP3A-mediated midazolam metabolism in critically ill neonates, infants, children and adults with inflammation and organ failure	75
Section III	First-pass CYP3A-mediated metabolism in children after oral drug administration	97
Chapter 5	First-pass CYP3A-mediated metabolism of midazolam in the gut wall and liver in preterm neonates	99
Chapter 6	Characterization of intestinal and hepatic CYP3A-mediated metabolism of midazolam in children using a physiological population pharmacokinetic modelling approach	127
Section IV	Midazolam as probe drug for other CYP3A substrates	157
Chapter 7	A pediatric covariate function for CYP3A-mediated clearance can scale clearance of selected CYP3A substrates in children	159
Section V	Summary, Conclusions, and Perspectives	187
Chapter 8	First-pass and systemic metabolism of cytochrome P450 3A substrates in neonates, infants, and children – Summary, Conclusions, and Perspectives	189
Chapter 9	Nederlandse Samenvatting	213
Appendices		237
Appendix I	Curriculum Vitae	239
Appendix II	List of publications	241
Appendix III	Nawoord/Acknowledgements	243